The role of IGF binding protein-3 as a parameter of activity in acromegalic patients

Abstract

Objective: The production of insulin-like growth factor binding protein- 3 (IGFBP-3), the main IGF-I binding protein, is regulated by GH, and its serum levels are increased in acromegaly. We investigated its potential value as a parameter of acromegaly activity or remission in comparison with IGF-I, taking GH supression below 2 μg/l after glucose load as the normal standard. Methods: Data from 40 acromegalic patients (12 males and 28 females, aged 28 to 79 years) were obtained retrospectively from stored samples. From these, 145 pairs of IGF-I/IGFBP-3 values were collected; in 67 of them, simultaneous measurement of GH after glucose loading allowed their classification as active or inactive acromegaly. Relationships between IGF-I, IGFBP-3 and GH after glucose load were assessed, as well as differences between IGF-I and IGFBP-3 levels in active and inactive acromegaly. Results: Significant positive correlation between IGF-I and IGFBP-3 in 145 samples was observed (r = 0.49, P<0.0001). As for the 67 samples in which activity or remission could be defined in terms of GH after glucose load, 50 were active and 17 inactive. Both IGF-I and IGFBP-3 significantly correlated with minimum GH (r = 0.53, P<0.0001 and r = 0.41, P<0.001 respectively). For both parameters, significant differences of means between active and inactive cases were observed (623 ± 296 vs 300 ± 108 ng/ml, P<0.0001 for IGF-I, and 4.1 ± 1.3 vs 3.2 ± 0.9 μg/ml, P<0.006 for IGFBP-3). Yet, when comparing in individual cases their classification as active or inactive with the finding of normal or increased IGF-I and IGFBP-3, among active cases 16% appeared as normal according to IGF-I, and 50% appeared as normal in terms of IGFBP-3. Among inactive cases, 23.5% appeared as active according to IGF-I, while 17.5% appeared as active in terms of IGFBP-3. Conclusion: Even though IGFBP-3 reflects GH secretion, it offers no advantage over IGF-I in the assessment of acromegaly, and it may underestimate disease activity in acromegalic patients.